Children's health sector is promising, China Resources 391.42 billion acquired Aonuo

[pharmaceutical network market analysis] at present, among the 3500 kinds of pharmaceutical preparations in China, only 1.7% are children's special dosage forms; among more than 4000 pharmaceutical enterprises in China, less than 5% are specialized in producing drugs for children, and the number of professional children's pharmaceutical brands is only one digit Facing the growing demand of children's drug market, more and more drug companies began to increase investment in this field On November 28, China Resources Sanjiu Pharmaceutical Co., Ltd (hereinafter referred to as "China Resources Sanjiu") announced that it would pay RMB 1.42 billion to acquire 100% equity of Aonuo (China) Pharmaceutical Co., Ltd (hereinafter referred to as "Aonuo pharmaceutical") held by Harbin Yuheng Pharmaceutical Co., Ltd It is reported that Aonuo pharmaceutical, founded on September 17, 1996, is a high-tech enterprise integrating production, R & D and sales Its main business line includes manufacturing of oral solution and other related pharmaceutical products, and its representative products include Aonuo, jinxinjinbeggars' special, vitamin C chewable tablets and other famous brands of children's calcium supplement The annual production capacity of its oral solution is 1 billion In the first half of 2018 and 2019, the operating revenue of Aonuo pharmaceutical is 359 million yuan and 169 million yuan, and the net profit is 148 million yuan and 72 million yuan The purchase of Aonuo by China Resources Sanjiu is mainly due to its optimistic view on its children's calcium supplement brand with good market scale and growth It is reported that children's health has always been a key development area of the business of self diagnosis and treatment (CHC) of Cr Sanjiu Over the years, Cr Sanjiu has been continuously enriching product lines, integrating high-quality resources of the industry, continuously expanding business, innovating and upgrading products to meet the health needs of each family member at all stages, full cycle and multi-level In fact, in order to protect children's drug market, in recent years, the government has been promoting many favorable policies to increase drug support for children For example, in 2012, the notice on printing and distributing the 12th Five Year Plan for national drug safety clearly proposed to encourage the research and development of appropriate dosage forms for children In 2017, 91 new varieties of children's drugs were added to the new medical insurance catalogue, and 540 drugs or dosage forms were clearly applicable to children Recently, in the newly revised Drug Administration Law, which will be formally implemented from December 1, the "children's drug use" will be included in the law, which makes it clear that the state will take effective measures to encourage the development and innovation of children's drugs, support the development of new varieties, dosage forms and specifications of children's drugs that meet the physiological characteristics of children, and give priority to the review and approval of children's drugs Thanks to the continuous good policy and the broad development space of drug market, at present, the major pharmaceutical enterprises have begun to increase their cultivation in the field of children's health, and the strong and strong cooperation among enterprises is increasingly frequent For example, in the early days, Cr 39, which expanded from mass products to specialized fields, was acutely aware of the business opportunities, and worked with Sanofi to rebuild a good baby brand In 2018, Hansen pharmaceutical, in order to develop a broader market, made a deep exploration of the hospital line and entered the retail market, launched a new specification of OTC version of Simo Soup for the elderly and children, opened a new era of Rx to OTC, and largely solved the problem of lack of children's digestive / gastrointestinal medicine market On January 21, 2019, poinsettia released a notice that its wholly-owned subsidiary, poinsettia Pharmaceutical Co., Ltd., and CenterLab investment holding limited, a wholly-owned subsidiary of shengdeda Pharmaceutical Co., Ltd., would jointly contribute to the establishment of Guangdong Pinsheng Pharmaceutical Technology Co., Ltd., saying that it would give full play to the advantages of both sides and build Pinsheng pharmaceutical into a leading enterprise in the field of children's medicine in mainland China Recently, the signing ceremony of strategic cooperation between China's leading enterprise of Pediatrics, dyne pharmaceutical, and pharmaceutical business giant Jiuzhoutong group was successfully completed The two sides have fully discussed and communicated with each other on the current situation, current business and future cooperation of the pharmaceutical industry, and determined the strategic cooperation direction of giving full play to their respective advantages and characteristics and working together in the future He said that he would enter every family more quickly, more deeply and more extensively, benefiting more Chinese children In recent years, people's health awareness has been constantly improved, "children need to use children's medicine" is becoming a social consensus With the continuous support of policies and the trend of vigorously developing new drugs with enterprises, it is expected that more and more real "children's drugs" will appear, and its market will also usher in the opportunity of outbreak.